The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk

References

• The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA_1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968–83
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2006. Diabetes Care 2006;29(Suppl 1):S4–42
   PubMed Web of Science ®Google Scholar
• American College of Endocrinology. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002;8(Suppl 1):5–11
   PubMedGoogle Scholar
• International Diabetes Federation Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005
   Google Scholar
• Abrahamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med 2004;164:486–91
   PubMed Web of Science ®Google Scholar
• Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence [review]. Diabetologia 2001;44:2107–14
   PubMed Web of Science ®Google Scholar
• Sudhir R, Mohan V. Postprandial hyperglycemia in patients with type 2 diabetes mellitus [review]. Treat Endocrinol 2002;1:105–16
   PubMedGoogle Scholar
• American Association of Clinical Endocrinologists and the American College of Endocrinology. Implementation conference for ACE outpatient diabetes mellitus consensus conference recommendations: position statement. Available at: http://www.aace.com/pub/pdf/guidelines/OutpatientImplementationPositionStatement.pdf. Accessed August 14, 2006.
   Google Scholar
• International Diabetes Federation. International diabetes federation launches first global guideline for management of type 2 diabetes. Available at: http://www.idf.org/home/index.cfm?4node=1460. Accessed August 7, 2006.
   Google Scholar
• Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003;26: 881–5
   Google Scholar
• Chiasson J-L, Josse RG, Gomis R, et al., for The STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–94
   Google Scholar
• Heine RJ, Balkau B, Ceriello A, et al. What does postprandial hyperglycaemia mean? Diabet Med 2004;21:208–13
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005;19:178–81
   PubMed Web of Science ®Google Scholar
• Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia [review]. Arch Intern Med 2003;163:1306–16
   PubMed Web of Science ®Google Scholar
• Parkin CG, Brooks N. Is postprandial glucose control important? Is it practical in primary care settings? Clin Diabetes 2002;20:71–6
   Google Scholar
• Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24:1734–8
   PubMed Web of Science ®Google Scholar
• Boland E, Monsod T, Delucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 2001;24:1858–62
   PubMed Web of Science ®Google Scholar
• Bonora E, Calcaterra F, Lombardi S, et al. Plasma glucose levels throughout the day and HbA1c interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 2001;24:2023–9
   PubMed Web of Science ®Google Scholar
• Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther 2003;5: 19–26
   Google Scholar
• Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006; 29:44–50
   PubMed Web of Science ®Google Scholar
• Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care 2006;29:2644–9
   PubMed Web of Science ®Google Scholar
• DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161: 397–404
   Google Scholar
• Nakagami T, The DECODA Study Group, on behalf of the International Diabetes Epidemiology Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47:385–94
   Google Scholar
• Hanefeld M, Fischer S, Julius U, et al., for the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39: 1577–83
   Google Scholar
• Shiraiwa T, Kaneto H, Miyatsuka T, et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 2005;336:339–45
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21–9
   PubMed Web of Science ®Google Scholar
• Yamanouchi T, Minoda S, Yabuuchi M, et al. Plasma 1,5-anhydro-d-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989;38:723–9
   PubMed Web of Science ®Google Scholar
• Yamanouchi T, Ogata N, Tagaya T, et al. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control. Lancet 1996;347:1514–18
   PubMed Web of Science ®Google Scholar
• Yamanouchi T, Inoue T, Ogata E, et al. Post-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycaemic state, in subjects with impaired glucose tolerance. Clin Sci (Lond) 2001;101:227–33
   PubMed Web of Science ®Google Scholar
• Dungan KM, Buse JB, Largay J, et al. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006;29:1214–19
   PubMed Web of Science ®Google Scholar
• Del Prato S. In search of normoglycaemia in diabetes: controlling postprandial glucose [review]. Int J Obes 2002;26(Suppl 3): S9–17
   Google Scholar
• Ceriello A, Garber AJ, Hirsch IB, et al. Postprandial glycemic control: achieving goals in type 2 diabetes. Medical Crossfire 2005;6:4–18
   Google Scholar
• Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–7
   PubMed Web of Science ®Google Scholar
• The DECODE study group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999;354:617–21
   PubMed Web of Science ®Google Scholar
• Brownlee M. Banting Lecture 2004. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–25
   Google Scholar
• Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707–8
   PubMed Web of Science ®Google Scholar
• Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006;29: 1486–90
   Google Scholar
• McCarter RJ, Hempe JM, Chalew SA. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 2006;29: 352–5
   Google Scholar
• Canadian Diabetes Association, Clinical Practice Guidelines Expert Committee. Monitoring glycemic control. Available at: http://www.diabetes.ca/cpg2003/download.aspx. Accessed April 4, 2005.
   Google Scholar
• Bergenstal RM, Gavin JR III, on behalf of the Global Consensus Conference on Glucose Monitoring Panel. The role of self-monitoring of blood glucose in the care of people with diabetes: report of a global consensus conference. Am J Med 2005; 118:1–6S
   Google Scholar
• Welschen LMC, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28:1510–17
   PubMed Web of Science ®Google Scholar
• Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004). Curr Med Res Opin 2005;21:173–83
   PubMed Web of Science ®Google Scholar
• Martin S, Schneider B, Heinemann L, et al, for the ROSSO Study Group. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006;49: 271–8
   Google Scholar
• Beebe CA. Self blood glucose monitoring: an adjunct to dietary and insulin management of the patient with diabetes. J Am Diet Assoc 1987;87:61–5
   PubMed Web of Science ®Google Scholar
• Davidson MB. Counterpoint: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money. Diabetes Care 2005;28:1531–3
   PubMed Web of Science ®Google Scholar
• Schwedes U, Siebolds M, Mertes G, for the SMBG Study Group. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non–insulin-treated type 2 diabetic patients. Diabetes Care 2002;25: 1928–32
   Google Scholar
• Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994;31: 215–19
   Google Scholar
• Kwon H-S, Cho J-H, Kim H-S, et al. Establishment of blood glucose monitoring system using the Internet. Diabetes Care 2004;27:478–83
   Google Scholar
• Jaber LA, Halapy H, Fernet M, et al. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother 1996;30:238–43
   PubMed Web of Science ®Google Scholar
• Estey AL, Tan MH, Mann K. Follow-up intervention: its effect on compliance behavior to a diabetes regimen. Diabetes Educ 1990;16:291–5
   Google Scholar
• Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10–16
   PubMed Web of Science ®Google Scholar
• Scorpiglione N, Belfiglio M, Carinci F, et al. The effectiveness, safety and epidemiology of the use of acarbose in the treatment of patients with type II diabetes mellitus. A model of medicine-based evidence. Eur J Clin Pharmacol 1999;55:239–49
   PubMed Web of Science ®Google Scholar
• Esposito K, Giugliano D, Nappo F, Marfella R, for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214–19
   Google Scholar
• Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171–5
   PubMed Web of Science ®Google Scholar
• Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337–44
   PubMed Web of Science ®Google Scholar
• Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β-cell hormone. Diabetes Technol Ther 2002;4:175–89
   PubMedGoogle Scholar
• Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26:784–90
   PubMed Web of Science ®Google Scholar
• Levetan C, Want LL, Weyer C, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003;26:1–8
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, et al., for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143: 559–69
   Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7
   PubMed Web of Science ®Google Scholar
• Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692–8
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205
   PubMed Web of Science ®Google Scholar